Bladder cancer remains a leading cause of cancer-related mortality in the United States, with most cases classified as conventional urothelial carcinoma. However, a substantial subset of patients presents with aggressive variant histologies, including sarcomatoid, plasmacytoid, and micropapillary subtypes. These varian...
Gabriella U. Nanjo, Zi-Rui Fu, S. Smani et al.· Urologic oncology· 0 citations
Hypoxia-inducible factor 2α (HIF-2α) is a central oncogenic driver in clear cell renal cell carcinoma (ccRCC) and a therapeutic target of the small-molecule inhibitor belzutifan. Genetic studies in murine models have suggested that hypoxia signaling may support T cell effector programs, raising concern that HIF-2α inhi...
Katrine N. Madsen, S. Kashima, H. Soulati et al.· Journal of Clinical Investig...· 0 citations
How emerging single-cell and spatial multi-omics technologies, integrated with artificial intelligence-based modeling, enable mapping of cell state landscapes and transitional trajectories, transforming lineage plasticity from a descriptive phenomenon into a measurable and predictable property of tumor evolution is dis...
Melanie Fraidenburg, Long-Jun Li, R. Kwon et al.· Cancer Letters· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
